12 Weeks of Combined Endurance and Resistance Training Reduces Innate Markers of Inflammation in a Randomized Controlled Clinical Trial in Patients with Multiple Sclerosis

Table 1

Clinical details of the study population.

	EX	SED	values
Gender (M/F)	13/16	6/10	0.634
Age ± SEM	47 ± 2	50 ± 3	0.516
BMI ± SEM	24 ± 1	24 ± 1	0.821
EDSS ± SEM	3 ± 0.2	3 ± 0.4	0.155
Type MS (CP/RR)	10/19	5/11	0.826
Medication (untreated/1st-line treatment/2nd-line treatment)	4/16/9	2/8/6	0.908

Results are shown as mean ± SEM. Patients were defined as untreated when a wash-out period of at least 3 months was respected before recruitment in the study. 1st-line treatment: IFN-β (Avonex, Betaferon, and Rebif) and glatiramer acetate (Copaxone); 2nd-line treatment: alemtuzumab (Campath), natalizumab (Tysabri), and fingolimod (Gilenya).
EX, exercise group; SED, sedentary control group; M, male; F, female; BMI, body mass index; EDSS, expanded disability status scale; MS, multiple sclerosis; CP, chronically progressive MS; RR, relapsing-remitting MS; SEM, standard error of the mean.